Pascal "Osi" Udekwu MBBS MBA MHA’s Post

Explore the #ISPP2023 Scientific Program and begin planning your schedule for the premier interdisciplinary conference on pain in infants, children, and adolescents, providing attendees with the latest research in the management of acute, procedural, and chronic pain. https://bit.ly/3YRTxug

In 2022, the APA released the ‘Text Revision’ for The Diagnostic and Statistical Manual 5th Edition (DSM-5-TR; APA, 2022). DSM-5-TR contains updates to underlying research on current concepts of mental disorder as well as introduction of new diagnostic terms and related codes and expands on culture-related diagnostic considerations. Enroll in our NEW online self-study course ""DSM-5-TR Updates"", presented by Dr. Jason Buckles, Ph.D., and the owner of Talkabout Inc., and learn about the changes contained within DSM-5-TR and how it may affect clinical considerations for assessment and diagnosis. (1.5 CE) https://buff.ly/3U8k9Ve

In this episode of the NP Pearls of Wisdom (POW) #Videocast, Dr. Julia Rogers, DNP, APRN, CNS, FNP-BC, FAANP chats with Dr. Beth Haney, DNP, FNP-C, FAANP, FAAN about getting involved in state and federal #legislature. #APRNs #NursePractitioners https://ow.ly/QwFg50QpiRV

Antipsychotics for dementia linked to more harms than previously acknowledged    Antipsychotic use in people with dementia is associated with higher risks of a wide range of serious health outcomes compared with non-use, according to a new study from a collaboration across the Universities of Manchester, Nottingham, Edinburgh and Dundee.   Higher rates of stroke, blood clots, heart attack, heart failure, fracture, pneumonia, and acute kidney injury were observed in the study funded by the National Institute for Health and Care Research (NIHR)and published in The BMJ (17/04/24)   The findings show a considerably wider range of harms associated with antipsychotic use in people with dementia than previously acknowledged in regulatory alerts, with risks highest soon after starting the drugs, underscoring the need for increased caution in the early stages of treatment.   Despite safety concerns, antipsychotics continue to be widely prescribed for behavioural and psychological symptoms of dementia such as apathy, depression, aggression, anxiety, irritability, delirium, and psychosis.   Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study | The BMJ   antipsychotics.pdf (psprings.co.uk)